• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病作为一种全身性疾病和对多学科治疗的需求。

Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care.

机构信息

Department of Gastroenterology and Hepatology, Yokohama City University Hospital, Yokohama, Japan.

出版信息

Gut Liver. 2023 Nov 15;17(6):843-852. doi: 10.5009/gnl220545. Epub 2023 Aug 10.

DOI:10.5009/gnl220545
PMID:37560797
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10651384/
Abstract

Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, and there has been a rapid increase in cases worldwide. NAFLD is rapidly becoming the leading cause of hepatocellular carcinoma and is also associated with an increased risk of cardiovascular disease or exacerbation of other organ diseases, thus posing a significant health problem from both a medical and a socioeconomic perspective. NAFLD is a systemic disease and requires the involvement of numerous medical professionals. Multidisciplinary collaboration, in which different professionals within different specialties come together and work together toward a common goal, supports better patient care by integrating perspectives of multiple experts and facilitating the exchange of opinions. Due to the large number of potential patients, gastroenterologists and hepatologists cannot manage the patients alone, and collaboration between specialists in various fields, including family doctors, dentists, nutritionists, and pharmacists is required for treatment of NAFLD. This review will discuss NAFLD from the perspective of various specialties and introduce multidisciplinary collaboration.

摘要

非酒精性脂肪性肝病(NAFLD)是目前最常见的慢性肝病,全球范围内的病例数迅速增加。NAFLD 正在迅速成为肝细胞癌的主要病因,并且还与心血管疾病风险增加或其他器官疾病恶化相关,因此从医学和社会经济学的角度来看,这是一个重大的健康问题。NAFLD 是一种全身性疾病,需要众多医疗专业人员的参与。多学科协作是指不同专业的不同专业人员聚集在一起,共同朝着一个共同的目标努力,通过整合多个专家的观点并促进意见交流,从而为患者提供更好的护理。由于潜在患者数量众多,胃肠病学家和肝病学家无法单独管理患者,因此需要包括家庭医生、牙医、营养师和药剂师在内的各个领域的专家进行合作,以治疗 NAFLD。本文将从多个专业的角度讨论 NAFLD,并介绍多学科协作。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/90198e4832f7/gnl-17-6-843-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/273862451014/gnl-17-6-843-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/1380203ceb82/gnl-17-6-843-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/227924c12ecf/gnl-17-6-843-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/877ae7506863/gnl-17-6-843-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/635376c1e961/gnl-17-6-843-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/3981664c79fd/gnl-17-6-843-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/90198e4832f7/gnl-17-6-843-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/273862451014/gnl-17-6-843-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/1380203ceb82/gnl-17-6-843-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/227924c12ecf/gnl-17-6-843-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/877ae7506863/gnl-17-6-843-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/635376c1e961/gnl-17-6-843-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/3981664c79fd/gnl-17-6-843-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b8/10651384/90198e4832f7/gnl-17-6-843-f7.jpg

相似文献

1
Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care.非酒精性脂肪性肝病作为一种全身性疾病和对多学科治疗的需求。
Gut Liver. 2023 Nov 15;17(6):843-852. doi: 10.5009/gnl220545. Epub 2023 Aug 10.
2
[Research advances in the pathogenesis of non-alcoholic fatty liver disease-associated liver cancer].非酒精性脂肪性肝病相关肝癌发病机制的研究进展
Zhonghua Gan Zang Bing Za Zhi. 2017 Feb 20;25(2):157-160. doi: 10.3760/cma.j.issn.1007-3418.2017.02.016.
3
[Research on the natural history of non-alcoholic fatty liver disease should be taken seriously].[应重视非酒精性脂肪性肝病自然史的研究]
Zhonghua Gan Zang Bing Za Zhi. 2017 Feb 20;25(2):81-84. doi: 10.3760/cma.j.issn.1007-3418.2017.02.001.
4
Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.2004 年至 2009 年美国非酒精性脂肪性肝病(NAFLD)与肝细胞癌(HCC)的相关性。
Hepatology. 2015 Dec;62(6):1723-30. doi: 10.1002/hep.28123. Epub 2015 Oct 24.
5
Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma.慢性乙型肝炎相关肝细胞癌患者并发非酒精性脂肪性肝病的预后影响。
J Gastroenterol Hepatol. 2020 Nov;35(11):1960-1968. doi: 10.1111/jgh.15026. Epub 2020 Mar 12.
6
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.非酒精性脂肪性肝病医生和患者耻辱感的全球调查。
J Hepatol. 2024 Mar;80(3):419-430. doi: 10.1016/j.jhep.2023.11.004. Epub 2023 Nov 18.
7
Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者的肝细胞癌
World J Gastroenterol. 2016 Oct 7;22(37):8294-8303. doi: 10.3748/wjg.v22.i37.8294.
8
New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.非酒精性脂肪性肝病的新治疗策略:关注非酒精性脂肪性肝炎的有前途药物。
Pharmacol Rep. 2020 Feb;72(1):1-12. doi: 10.1007/s43440-019-00020-1. Epub 2020 Jan 8.
9
Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.糖尿病视网膜病变作为非酒精性脂肪性肝病中与肝细胞癌发生相关的危险因素。
Dig Dis. 2019;37(3):247-254. doi: 10.1159/000493580. Epub 2019 Jan 9.
10
Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.非酒精性脂肪性肝病相关肝细胞癌的临床特征:一项人体研究综述
Clin J Gastroenterol. 2015 Feb;8(1):1-9. doi: 10.1007/s12328-014-0548-5. Epub 2015 Jan 10.

引用本文的文献

1
Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis.体重减轻对代谢功能障碍相关脂肪性肝炎和肝纤维化的影响。
Curr Diab Rep. 2025 Feb 18;25(1):23. doi: 10.1007/s11892-025-01579-1.
2
The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial.在伴有 2 型糖尿病的非酒精性脂肪性肝病患者中,厄格列净的疗效:一项随机对照试验。
Medicine (Baltimore). 2024 Nov 8;103(45):e40356. doi: 10.1097/MD.0000000000040356.
3
Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis.

本文引用的文献

1
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990-2019: A DALY-based analysis of the Global Burden of Disease 2019 study.全球原发性肝癌负担及其与潜在病因、社会人口地位和性别差异的关系:基于残疾调整生命年的 2019 年全球疾病负担研究分析。
Clin Mol Hepatol. 2023 Apr;29(2):433-452. doi: 10.3350/cmh.2022.0316. Epub 2023 Jan 4.
2
Global incidence and prevalence of nonalcoholic fatty liver disease.全球非酒精性脂肪性肝病的发病率和患病率。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S32-S42. doi: 10.3350/cmh.2022.0365. Epub 2022 Dec 14.
3
中度至重度特应性皮炎成年个体中非酒精性脂肪性肝病的患病率
J Clin Med. 2023 Sep 19;12(18):6057. doi: 10.3390/jcm12186057.
Summary of Revisions: Standards of Care in Diabetes-2023.
修订摘要:《2023年糖尿病护理标准》
Diabetes Care. 2023 Jan 1;46(Suppl 1):S5-S9. doi: 10.2337/dc23-Srev.
4
Screening strategy for non-alcoholic fatty liver disease.非酒精性脂肪性肝病的筛查策略。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S103-S122. doi: 10.3350/cmh.2022.0336. Epub 2022 Nov 30.
5
Periodontal Treatment and Usual Care for Nonalcoholic Fatty Liver Disease: A Multicenter, Randomized Controlled Trial.牙周治疗和非酒精性脂肪性肝病的常规护理:一项多中心、随机对照试验。
Clin Transl Gastroenterol. 2022 Nov 1;13(11):e00520. doi: 10.14309/ctg.0000000000000520.
6
Non-alcoholic fatty liver disease: a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function.非酒精性脂肪性肝病:一种受衰老和性别影响,并受脂肪组织和肠道功能影响的多系统疾病。
Proc Nutr Soc. 2022 May;81(2):146-161. doi: 10.1017/S0029665121003815. Epub 2021 Nov 22.
7
Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial.托格列净与吡格列酮联合治疗非酒精性脂肪性肝病:ToPiND 随机对照试验的扩展。
Hepatol Commun. 2022 Sep;6(9):2273-2285. doi: 10.1002/hep4.1993. Epub 2022 May 16.
8
The effect of polypharmacy on quality of life in adult patients with nonalcoholic fatty liver disease in the United States.美国非酒精性脂肪性肝病成年患者中,多种药物治疗对生活质量的影响。
Qual Life Res. 2022 Aug;31(8):2481-2491. doi: 10.1007/s11136-022-03090-6. Epub 2022 Jan 22.
9
Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease.通过瞬时弹性成像测量的晚期肝纤维化可预测非酒精性脂肪性肝病患者慢性肾脏病的发生。
Diabetologia. 2022 Mar;65(3):518-527. doi: 10.1007/s00125-021-05627-9. Epub 2021 Dec 21.
10
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病成人患者结局的前瞻性研究。
N Engl J Med. 2021 Oct 21;385(17):1559-1569. doi: 10.1056/NEJMoa2029349.